SCHEMBL8941445

SCHEMBL8941445

COC(=O)COS(=O)(=O)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.44
POLB P06746 3/20 0.42
CA12 O43570 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
NR1I2 O75469 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
AKT1 P31749 1/20 0.41
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8866856 0.84 STAT3 (0.57) STAT3MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL20581776 0.84 GAA (0.45) STAT3POLBCA12CA7CA9
SCHEMBL10488009 0.83 GAA (0.50) POLBCA12CA9MEN1KMT2A
SCHEMBL28134943 0.83 CA12 (0.47) POLBCA12CA7CA9CA14
SCHEMBL11747444 0.81 POLB (0.44) STAT3POLBMEN1KMT2ATSHR
SCHEMBL10012134 0.81 STAT3 (0.39) STAT3POLBNR1I2ALDH1A1MAPT
SCHEMBL9243189 0.81 ALOX15 (0.47) STAT3POLBTSHRSMN1; SMN2ALDH1A1
SCHEMBL27810403 0.81 STAT3 (0.50) STAT3POLBCA12CA9MEN1
SCHEMBL9243186 0.79 ENPP3 (0.43) STAT3KMT2ATSHRSMN1; SMN2ALDH1A1
SCHEMBL28659206 0.79 ALOX15 (0.45) STAT3POLBTSHRSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9130244-B2 Nonaqueous electrolyte solution and electrochemical element using same UBE INDUSTRIES, LTD. (JP) 2015-09-08 US disclosed
EP-2908376-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME Ube Industries, Ltd. (JP) 2015-08-19 EP disclosed
EP-2479831-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME Ube Industries, Ltd. (JP) 2012-07-25 EP disclosed
US-20120171581-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME UBE INDUSTRIES, LTD. (JP) 2012-07-05 US disclosed
CN-101298415-A Preparation of non-steroidal anti-inflammatory medicine biphenylacetic acid WUXUE XUNDA PHARMACEUTICAL IND (CN) 2008-11-05 CN disclosed
US-5510379-A USEFUL FOR TREATING HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1996-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120171581-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME SLC8A1, OR10J3, SLC8B1 STAT3 1897/4885POLB 3715/4885CA12 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.